{"slideshow_credits": null, "snippet": "The acquisition is part of efforts by AstraZeneca to restock its drug pipeline after its established products have come under threat from makers of generic drugs.", "abstract": "The acquisition is part of efforts by AstraZeneca to restock its drug pipeline after its established products have come under threat from makers of generic drugs.", "section_name": "Business Day", "print_page": null, "document_type": "blogpost", "byline": {"person": [{"firstname": "Mark", "role": "reported", "lastname": "SCOTT", "rank": 1, "organization": ""}], "original": "By MARK SCOTT"}, "web_url": "http://dealbook.nytimes.com/2013/06/10/astrazeneca-in-1-15-billion-deal-for-pearl-therapeutics/", "lead_paragraph": null, "headline": {"main": "AstraZeneca in Deal for Pearl Therapeutics Worth Up to $1.15 Billion ", "print_headline": "Restocking A Pipeline", "kicker": "DealBook"}, "_id": "51b8952a7e0d9c0839d2798f", "word_count": "157", "multimedia": [], "pub_date": "2013-06-10T07:16:42Z", "source": "The New York Times", "news_desk": null, "keywords": [{"name": "organizations", "value": "Pearl Therapeutics Inc", "is_major": "Y", "rank": "1"}, {"name": "organizations", "value": "AstraZeneca PLC", "is_major": "Y", "rank": "2"}, {"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "3"}], "blog": [], "subsection_name": "Dealbook", "type_of_material": "Blog"}